The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.
MindMed’s stock soars 58% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
Read Next
- Indian exports not adversely impacted by rupee exchange rate policy, cenbank says, ET BFSI
- NVIDIA’s Grace and Grace Hopper CPUs Propel Ansys Workloads to New Heights
- Bluesky CEO Jay Graber says X rival is ‘billionaire proof’
- Trump AG pick Matt Gaetz says he’s withdrawing
- Italy’s CONSOB issues orders for blocking of access to five unauthorised investment websites
- Will create 4 million women in the workforce over the next three years: FICCI President, ET BFSI
- Alphabet shares slide 6% following DOJ push for Google to divest Chrome
